Motus GI Expands Intellectual Property Portfolio with Issuance of New U.S. Patent for the Pure-Vu® System

Issued patent further bolsters Company’s intellectual property estate, supporting strategic pathway for Pure-Vu® System to become standard of care for inpatient colonoscopy

Motus GI Holdings, Inc., announced today that the U.S. Patent and Trademark Office (USPTO) has issued patent No. 10,179,202 titled, “Systems and methods for cleaning body cavities and for endoscopic steering,” which protects the Company’s flagship product, the Pure-Vu® System.

The Pure-Vu® System is a U.S. Food and Drug Administration (“FDA”) cleared medical device indicated to help facilitate the cleaning of a poorly prepared colon during the colonoscopy procedure. The device integrates with standard and slim colonoscopes to enable safe and rapid cleansing during the procedure while preserving established procedural workflow and techniques.

“We continue to add to our extensive IP portfolio which is now comprised of over 20 patents worldwide, covering all aspects of the Pure-Vu® System. Intellectual property continues to be a key focus, particularly as we prepare for the commercial launch of Pure-Vu® next quarter,” commented Tim Moran, Chief Executive Officer of Motus GI. “To complement our strong IP portfolio, we are actively generating robust clinical data which we believe demonstrates the Pure-Vu® System’s ability to reduce the number of delayed and incomplete procedures in the inpatient setting, a significant issue where more than half of patients present with an insufficiently prepped colon, leading to additional costs. Our ongoing REDUCE study is evaluating the Pure-Vu® System’s ability to consistently and reliably cleanse the colon to facilitate a successful colonoscopy in a timely manner in patients who are indicated for a diagnostic colonoscopy.”

 

WE WELCOME YOUR VIEWS

Please enter your comment!
Please enter your name here